Authors
Rustambayova G.R., Madjidova S.R.
National Centre of Ophthalmology named after acad. Zarifa Aliyeva, Baku, Azerbaijan
Abstract
Rationale: Vogt-Koyanagi-Harada disease is a multisystem disease characterized by granulomatous panuveitis with exudative retinal detachment, choroidal thickening, often associated with neurological and cutaneous manifestations. One of the main complications that significantly reduces the patient’s visual acuity is the development of choroidal neovascular membranes.
Objective: to describe the use of intravitreal bevacizumab for choroidal neovascular membrane associated with Vogt-Koyanagi-Harada syndrome.
Methods: A clinical case of 25-year-old female patient with Vogt-Koyanagi-Harada disease complicated by the development of a subretinal neovascular membrane.
Results. After the diagnosis of Vogt-Koyanagi-Harada syndrome, the patient with Vogt-Koyanagi-Harada syndrome was prescribed intravitreal injections of an anti-VEGF in addition to systemic anti-inflammatory therapy. After 2 intravitreal injections of bevacizumab, an increase in visual acuity, resorption of subretinal fluid and blood, cystic macular edema, and a decrease in the size of the subretinal neovascular membrane were observed.
Conclusion. Chronicization of the Vogt-Koyanagi-Harada syndrome syndrome can lead to permanent visual loss associated with subretinal neovascular membrane. In such patients, a combined approach to treatment may be required. Intravitreal use of bevacizumab in combination with general anti-inflammatory treatment in our case led to regression of a subretinal neovascular membrane and visual acuity improvement.
Keywords: Vogt-Koyanagi-Harada syndrome; subretinal neovascular membrane; antivasoproliferative therapy.
References
1. Maezawa N, Yano A, Taniguchi M et al. The role of cytotoxic T lymphocytes in the pathogenesis of Vogt-Koyanagi-Harada disease. Ophthalmologica. 1982;185(3):179-186. doi: 10.1159/000309240.
2. Lertsumitkul S, Whitcup SM, Nussenblatt RB et al. Subretinal fibrosis and choroidal neovascularization in Vogt-Koyanagi-Harada syndrome. Graefes Arch Clin Exp Ophthalmol., 1999 Dec;237(12):1039-45. doi: 10.1007/s004170050342.
3. Grossniklaus HE., Ling JX., Wallace TM et al. Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization Molecular Vision, 2002;8:119-126.
4. Chan WM, Lai TYY, Liu DTL et al. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Am J Ophthalmol. 2007 Jun;143(6):977-983. doi: 10.1016/j.ajo.2007.02.039. Epub 2007 Apr 24.
5. Arias L, Planas N, Prades S et al. Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia: 6-month results. Br J Ophthalmol. 2008 Aug;92(8):1035-9. doi: 10.1136/bjo.2007.130260.
6. Tran THC, Fardeau C, Terrada C et al. Intravitreal bevacizumab for refractory choroidal neovascularization (CNV) secondary to uveitis. Graefes Arch Clin Exp Ophthalmol., 2008;246(12):1685-1692.
7. Wu L., Evans T., Saraiva M. et al. Intravitreal bevacizumab for choroidal neovascularization secondary to Vogt-Koyanagi-Harada syndrome. Jpn J Ophthalmo.l 2009;53:57-60.
8. Nowilaty S.R., Bouhaimed M. et al. Photodynamic therapy for subfoveal choroidal neovascularisation in Vogt-Koyanagi-Harada disease. Br J Ophthalmol. 2006 Aug; 90(8): 982–986.doi: 10.1136/bjo.2006.091538.
